---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-032263"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-07-07T12:54:20+00:00"
generated_at: "2026-07-07T12:55:05.497731+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies reports Q2 2026 CyPath Lung sales up >200% YoY, record quarter

## Summary
- Q2 2026 CyPath Lung sales volume >200% YoY and >30% over Q1 2026.
- Nearly 3,000 tests performed since commercial launch.
- 155% increase in physician offices ordering CyPath Lung vs Q2 2025.
- Company expects to report Q2 2026 financial results in August.
- Initiatives include longitudinal study, oncology expansion, asthma/COPD tests.

## SEC filing metadata
- accession: 0001493152-26-032263
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-07-07T12:54:20+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226032263/0001493152-26-032263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226032263/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-032263
- JSON: https://secwatch.observer/filing/0001493152-26-032263.json
- Plain text: https://secwatch.observer/filing/0001493152-26-032263.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.